达比加群酯联合尼可地尔治疗经皮冠状动脉介入治疗术后心绞痛的效果及对N末端B型利钠肽前体与可溶性CD105的影响  

Effect of Dabigatrenate combined with Nicodil in the Treatment of Angina Pectoris after Percutaneous Coronary Intervention and Its Influence on N-terminal B-type Natriuretic Peptide Precursor and Soluble CD105

作　　者：陈传军 王静[1] 贾利清 曲涛 CHEN Chuan-Jun;WANG Jing;JIA Li-Qing;QU Tao(Department of Cardiology,Inner Mongolia Baotou Gang Hospital/The Third Affiliated Hospital of Inner Mongolia Medical University,Baotou 014010,China)

机构地区：[1]内蒙古包钢医院/内蒙古医科大学第三附属医院心内科,内蒙古包头014010

出　　处：《中国药物经济学》2023年第9期71-74,79,共5页China Journal of Pharmaceutical Economics

摘　　要：目的探讨尼可地尔联合达比加群酯治疗经皮冠状动脉介入治疗(PCI)术后心绞痛的疗效及对N末端B型利钠肽前体(NT-proBNP)、可溶性CD105(sCD105)水平的影响。方法选取2018年4月至2022年12月内蒙古包钢医院收治的PCI术后心绞痛患者70例作为研究对象,随机分为对照组和观察组,各35例。对照组服用尼可地尔治疗,观察组服用尼可地尔联合达比加群酯治疗。记录两组患者治疗前后心绞痛发作次数和持续时间,评价临床疗效和安全性,同时检测患者NT-proBNP、sCD105水平。结果治疗后两组心绞痛发作次数、持续时间明显减少(P<0.05),且观察组明显少于对照组(P<0.05);观察组治疗有效率为97.14%,明显高于对照组的80.00%(P<0.05);治疗后,两组NT-proBNP水平明显下降(P<0.05),且观察组明显低于对照组(P<0.05);治疗前后两组sCD105水平比较差异无统计学意义(P>0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论PCI术后心绞痛采用尼可地尔联合达比加群酯治疗,具有较好的抗心绞痛效果,出血风险低,并可有效改善心脏损伤标志物,但对sCD105无明显影响。Objective To explore the effect of nicodil combined with dabigatrun on angina pectoris after percutaneous coronary intervention(PCI)and its influence on N-terminal B-type natriuretic peptide precursor(NT-proBNP)and soluble CD105(sCD105).Methods A total of 70 patients with angina pectoris after PCI treated in Inner Mongolia Baogang Hospital from April 2018 to December 2022 were selected as the study objects and randomly divided into control group and observation group,with 35 patients in each group.Control group was treated with nicodil,observation group was treated with nicodil combined with dabigatran ester.The frequency and duration of angina pectoris attacks before and after treatment were recorded in the two groups,the clinical efficacy and safety were evaluated,and the levels of NT-proBNP and sCD105 were detected.Results After treatment,the frequency and duration of angina pectoris in both groups were significantly reduced(P<0.05),and the observation group was significantly less than the control group(P<0.05).The effective rate of the observation group was 97.14%,which was significantly higher than that of the control group(80.00%)(P<0.05).After treatment,the level of NT-proBNP in both groups was significantly decreased(P<0.05),and the observation group was significantly lower than the control group(P<0.05).There was no significant difference in sCD105 level between the two groups before and after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of angina pectoris after PCI,nicodil combined with dabigatran ester has good anti-angina pectoris effect,low bleeding risk,and can effectively improve cardiac biomarkers,but has no significant effect on sCD105.

关 键 词：尼可地尔 达比加群酯 经皮冠状动脉介入治疗后心绞痛 N末端B型利钠肽前体 可溶性CD105 

分 类 号：R541.4[医药卫生—心血管疾病] R972[医药卫生—内科学]